According to two new studies presented Thursday at the San Antonio Breast Cancer Symposium, active monitoring of ductal ...

Two major studies challenge long-standing practices. The first shows active monitoring might safely replace surgery for some ...

The first study comparing surgery to active monitoring as treatment for ductal carcinoma in situ (DCIS) finds women who carefully monitor the precancerous cells are no more likely to develop breast ...

Researchers examined pooled data from two clinical trials that enrolled patients with low- or intermediate-grade ductal ...

A new study, published in the New England Journal of Medicine, examines whether removing lymph nodes is always necessary in ...

An analysis of phase 3 trials found tamoxifen significantly reduced 15-year ipsilateral breast recurrence in patients with ...

Two recent studies explore options for early-stage breast cancer patients to reduce surgery. One suggests active monitoring ...

Active monitoring for low-risk ductal carcinoma in situ (DCIS) did not lead to a higher rate of ipsilateral invasive cancer ...

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, ...

In this prespecified secondary analysis of the Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET ...

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the ...

WASHINGTON (dpa-AFX) - According to the American Cancer Society, every year over 50,000 women suffer from ductal carcinoma in situ or DCIS, often known as 'zero-stage breast cancer' or 'precancer'.